atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

March 3, 2021 Articles 8:00 am

atai Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D financing round. The round was led by our existing investors Apeiron Investment Group, the family office of atai’s founder Christian Angermayer, Thiel Capital, and joined by Woodline Partners LP.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit

JOIN THE ATAI #INSIGHTNETWORK

Sign up to receive the latest news on atai.